山东药玻(600529) - 2015 Q1 - 季度财报
SPGSPG(SH:600529)2015-04-21 16:00

Financial Performance - Operating income rose by 6.63% to CNY 415,868,291.43 year-on-year[6] - Net profit attributable to shareholders increased by 8.09% to CNY 32,188,025.00 compared to the same period last year[6] - Basic earnings per share rose by 8.33% to CNY 0.13[6] - Total operating revenue for the current period reached ¥415,868,291.43, an increase of 6.9% compared to ¥390,024,307.40 in the previous period[23] - Net profit for the current period was ¥32,196,707.39, which is a 7.5% increase compared to ¥29,899,737.94 from the previous period[24] - Earnings per share (EPS) for the current period was ¥0.13, up from ¥0.12 in the previous period, indicating a growth of 8.3%[25] Cash Flow - Cash flow from operating activities surged by 60.52% to CNY 70,509,040.49 year-on-year[6] - Cash inflow from operating activities totaled ¥471,678,106.76, an increase from ¥421,634,471.19 in the previous period, marking a growth of 11.9%[30] - Operating cash flow net amount for Q1 2015 was CNY 66,678,040.75, an increase of 50.8% compared to CNY 44,220,744.62 in the previous period[35] - The total cash inflow from operating activities was CNY 437,788,114.26, up from CNY 390,908,750.07 in the previous period, reflecting an increase of 12.0%[35] - The cash flow from financing activities net amount was CNY 30,612,955.33, a recovery from a negative cash flow of -CNY 31,007,324.94 in the previous period[36] Assets and Liabilities - Total assets increased by 2.73% to CNY 2,895,220,083.86 compared to the end of the previous year[6] - Total liabilities amounted to CNY 738,075,110.57, up from CNY 692,561,460.85, indicating an increase of approximately 6.56%[18] - Current liabilities totaled CNY 738,075,110.57, reflecting an increase from CNY 692,561,460.85, which is a growth of about 6.56%[18] - The company's equity attributable to shareholders reached CNY 2,148,055,018.11, up from CNY 2,116,330,672.48, representing an increase of approximately 1.5%[18] - Current assets totaled CNY 1,603,632,685.83, an increase from CNY 1,526,403,446.05, reflecting a growth of about 5.06%[17] Expenses - Sales expenses increased by 30.18% due to higher product sales and increased freight and travel costs[12] - Management expenses increased by 39.55% primarily due to higher product quality management costs[12] - Total operating costs amounted to ¥373,300,540.65, up from ¥349,820,478.22, reflecting a growth of 6.7%[23] - Sales expenses increased to ¥40,851,492.89 from ¥31,381,634.99, reflecting a rise of 30.5%[24] - Management expenses rose to ¥30,874,311.73, compared to ¥22,124,442.12, indicating an increase of 39.5%[24] Investments - Cash outflow for investment activities totaled CNY 69,953,539.03, compared to CNY 30,186,347.83 in the previous period, representing a 131.7% increase[35] - The company reported a net cash flow from investment activities of -CNY 69,931,866.02, worsening from -CNY 30,186,347.83 in the previous period[35] Other Financial Metrics - The weighted average return on net assets increased by 0.06 percentage points to 1.52%[6] - Financial expenses decreased to ¥419,454.76 from ¥1,125,476.40, showing a reduction of 62.8%[24] - The company reported an increase in comprehensive income to ¥32,196,707.39 from ¥29,899,737.94, reflecting a growth of 7.5%[25]